After another swing and a miss for AstraZeneca's Fasenra in chronic obstructive pulmonary disease (COPD), the company is pivoting to other options in its portfolio that might have potential to treat ...
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the MANDARA Phase III trial showed AstraZeneca’s FASENRA (benralizumab) met the primary endpoint of the trial and demonstrated ...
Please provide your email address to receive an email when new articles are posted on . The approval follows positive results from the TATE trial. A new 10 mg dose will be available to accommodate ...
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss Syndrome, is a rare autoimmune disorder characterized by necrotizing vasculitis of small-to medium-sized blood ...
Please provide your email address to receive an email when new articles are posted on . This patient population had “better outcomes” when receiving benralizumab with or without prednisolone vs.
The European Commission has approved the Committee for Medicinal Products for Human Use (CHMP) recommendation to change the terms of marketing authorization for Fasenra (benralizumab). It can now also ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. FASENRA PEN contains the active ingredient benralizumab. FASENRA PEN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results